ArticleAnnals of nuclear medicine2026
18 F-FDG PET/CT Derived Volumetric Parameters Can Predict Outcome in Pediatric Ewing Sarcoma.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the prognostic and predictive value of metabolic and volumetric parameters obtained from baseline (PET1) and post-chemotherapy (PET2) 18 F-FDG PET/CT in pediatric Ewing sarcoma (EWS) patients, focusing on their associations with histopathologic response, metastatic presentation, overall survival (OS), and progression-free survival (PFS).
methodsThis retrospective single tertiary academic center study included 55 pediatric EWS patients who underwent PET1. Twenty-four patients also had PET2. SUVmax, SUVpeak, metabolic tumor volume (MTV), total lesion glycolysis (TLG) and their percentage changes (∆) between PET scans were calculated using absolute (SUV 2.0 and 2.5) and relative (40% and 45%) thresholds. Anatomic tumor volume was also measured. Histopathologic evaluation was available for 40 patients with PET1 and 18 patients with PET2. Associations were analyzed using logistic and Cox regression models.
resultsBaseline metabolic and volumetric PET parameters were significantly higher in patients with presenting metastasis. Among these, TLG (45%) was identified as the only independent predictor of metastatic presentation (OR = 1.026, p = 0.019). Baseline MTV (2.0) was independently associated with shorter OS (HR = 1.026, p = 0.003) and PFS (HR = 1.035, p = 0.038). Combined stratification using MTV (2.0) and histologic response revealed that patients with an unfavorable histologic response but low MTV demonstrated superior OS and PFS rates than those with an unfavorable response and high MTV. The survival outcomes of patients with a favorable histologic response and high MTV were comparable to those with an unfavorable response and low MTV. However, PET parameters did not reliably predict histopathologic response in this cohort.
conclusionsBaseline MTV (2.0) demonstrated prognostic value for OS and PFS, while TLG (45%) independently predicted metastatic presentation in pediatric EWS. The combination of MTV (2.0) and histologic response appears to provide complementary prognostic information. Prospective, multicenter studies with standardized imaging and treatment protocols are warranted to validate the role of volumetric 18 F-FDG PET parameters in clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.